Akcea Therapeutics (AKCA) Misses Q4 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Stifel Downgrades Akcea Therapeutics, Inc. (AKCA) to Hold Ahead of FDA AdCom
February 27, 2018 6:39 AM ESTStifel downgraded Akcea Therapeutics, Inc. (NASDAQ: AKCA) from Buy to Hold with a price target of $20.00.
Analyst Stephen Willey said they believe FDA's upcoming (May 10) Advisory Committee meeting represents a potential source of volatility which we would prefer to watch unfold from the sidelines... More
